There is a trend among stock market analysts when it comes to Chesterbrook-based AmerisourceBergen Corp., and it is optimism about the future.

The wholesale drug company has amassed ratings from “A” to “strong buy,” “outperform,” “buy” and “neutral,” according to an update in American Banking & Market News.

Most analysts are pegging the stock’s target price to rise beyond its 52-week high to nearly $80 or more, the article stated.

In its last earnings report, AmerisourceBergen beat analysts’ expectations for both revenue and earnings per share, which is now slated to finish the year at $3.90.

Read more about the local stock activity in American Banking & Market News here.